Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 11, 2005

View Archived Issues

Angiotensin II type 1 receptor antagonism attenuates experimental colitis

UPF-680's positive effects on biliary function

New study raises the red flag for PDE4 inhibitors

FDA accepts for review CIP-Isotretinoin NDA

Kemia begins phase I trials with novel kinase inhibitor for inflammatory indications

Viventia Biotech reports update on VB4-845 for bladder cancer

Enzo reports promising preclinical results of potential bone growth compound

Promising preclinical data reported for IBD compound at Advitech

Abmaxis and MaimoniDex establish alliance for RA drug discovery

ADX-47273 - a novel mGluR5-positive allosteric modulator

Treg cells exposed to JJ-316 protect against EAE

hVps34, a class 3 PI3K, identified as a potential antiobesity target

SGN-30's growth arrest and synergistic effects with chemotherapeutics for HD

Testosterone MDTS improves libido of premenopausal women with low testosterone levels

Anidulafungin reported well tolerated in patients with invasive candidiasis/candidemia

Update on the antibacterial effects and the pharmacokinetics of ceftobiprole

Ambien CR available in U.S. for insomnia

New preclinical data on the effects of tacrolimus in skin disorders

Critical Therapeutics plans Zyflo launch

Novel coagulation factor Xa inhibitors emerge from Boehringer Ingelheim R&D

Therapeutic agents for osteoporosis reported in recent patent literature

Vitespen reported to improve survival of patients with metastatic melanoma

Novel therapeutic agents for HIV infection disclosed

Novel immunomodulatory agents claimed

New potential analgesic agents in early development

New data on the efficacy of imiquimod in lentigo maligna